Heparin ablates force development during platelet mediated clot retraction

Thrombosis and Haemostasis

Volumn 75, Issue 4, 1996, Pages 674-678

  Carr Jr , Marcus E ^a,b,c   Carr, Sheryl L ^a,b   Greilich, Philip E ^b  

^a Coagul Special Studies Laboratory ^*  (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HUNTER HOLMES MCGUIRE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BATROXOBIN; COLLAGEN; HEPARIN; HIRUDIN; PROTAMINE SULFATE; THROMBIN;

ARTICLE; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FIBRIN POLYMERIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STUDY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE RELEASE REACTION; THROMBOCYTE RICH PLASMA;

EID: 0029993695     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650341     Document Type: Article

References (29)

1. Salzman EW, Deykin D, Shapiro RM, Rosenberg RD. Management of heparin therapy. Controlled prospective trial. N Engl J Med 1975; 292: 1046-50.
2. Buchanan MR, Nguyen P, Van Ryn J, Ofosu FA, Hirsh J. DDAVP reduces the platelet defect associated with heparin. Circulation 1986; 74 (Suppl II): II-95.
3. Heiden D, Mielke Jr CH, Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxtryptamine release. Br J Haematol 1977; 36: 427-36.
4. Suzuki K, Nishioka J, Hashimoto S. Inhibition of factor VIII-associated platelet aggregation by heparin and dextran sulfate, and its mechanism. Biochim Biophys Acta 1979; 585: 416-26.
5. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand Factor-dependent Platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-93.
6. Carr ME, Zekert SL. Force monitoring of clot retraction during DDAVP therapy for the qualitative platelet disorder of uraemia: Report of a case. Blood Coagul Fibrinolysis 1991; 2: 303-8.
7. Carr ME, Zekert SL. Measurement of platelet mediated force development during plasma clot formation. Am J Med Sci 1991; 302: 13-8.
8. Greilich PE, Carr ME, Carr SL, Chang AS. Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth Analg 1995; 80: 459-65.
9. Niewiarowski S, Regoeczi E, Stewart GJ, Senyi AF, Mustard JF. Platelet interaction with polymerizing fibrin. J Clin Invest 1972; 51: 685-700.
10. Niewiarowski S, Regoeczi E, Mustard JF. In New York Academy of Sciency: Conference on platelets and their role in hemostasis. Abstract n. 6, 1971.
11. de Gaetano G, Bottecchia D, Vermylen J. Retraction of reptilase-clots in the presence of agents inducing or inhibiting the platelet adhesion-aggregation reaction. Thromb Res 1973; 2: 71-84.
12. 1. Thrombin Res 1974; 4: 189-92.
13. de Gaetano G, Bottecchia D, Vermylen J. Effect of platelets on clot structuration. A thromboelastographic study. Thromb Res 1973; 3: 425-35.
14. Carr ME, Powers PL. Effect of glycosaminoglycans on thrombin- and atroxin-induced fibrin assembly and structure. Thromb Haemost 1989; 62: 1057-61.
15. Carr ME, Carr SL. Abnormal clot retraction, altered fibrin structure and normal platelet function in multiple myeloma. Am J Physiol 1994; 266: H1195-201
16. Clauss A. A rapid physiological coagulation method for determination of fibrinogen. Acta Haematol 1957; 17: 237-46.
17. Carr ME, Gabriel DA. The effect of dextran 70 on the structure of plasma-derived fibrin gels. J Lab Clin med 1980; 96: 985-93.
18. Carr ME, Gabriel DA. Dextran-induced changes in fibrin fiber size and density based on wavelength dependence of gel turbidity. Macromolecules 1980; 13: 1473-7.
19. Carr ME, Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 1978; 11: 46-50.
20. Carr ME, Gabriel DA, McDonagh J. Influence of Calcium on the Structure of Reptilase and Thrombin Derived Fibrin Gels. Biochem J 1986; 239: 513-6.
21. Carr ME. Fluid Phase Coagulation Events Have Minimal Impact on Plasma Fibrin Structure. Am J Med Sci 1988; 295: 433-7.
22. Carr ME. Fibrin Formed in Plasma Is Composed of Fibers More Massive Than Those Formed From Purified Fibrinogen. Thromb Haemost 1988; 59: 535-9.
23. Harker L, Malpass TW, Branson HE, Hessel II EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-34.
24. John LC, Rees GM, Kovacs IB. Effect of heparin on in vitro platelet reactivity in cardiac surgical patients - a comparative assessment by whole blood platelet aggregometry and haemostatometry. Thromb Res 1992; 66: 649-56.
25. John LC, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 1993; 105: 816-22.
26. John LC, Rees GM, Kovacs IB. Different anticoagulants and platelet reactivity in cardiac surgical patients. Ann Thorac Surg 1993; 56: 899-902.
27. Shainoff JR, Estafanous G, Yared JP, DiBello PM, Kottke-Marchant K, Loop FD. Low factor XIIIa levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994; 108. 437-45.
28. Carr ME, Carr SL. At high heparin concentrations, protamine concentrations which reverse anticoagulant effects are insufficient to reverse heparin antiplatelet effects. Thromb Res 1994; 75: 617-30.
29. Brister SJ, Ofosu FA, Heigenhauser GJF, Gianese F, Buchanan MR. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice. Thromb Haemost 1994; 71: 468-73.